[April 14, 2014]

Research and Markets: Global Infanrix Hexa (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

Research and Markets (http://www.researchandmarkets.com/research/tb2h6k/infanrix_hexa) has announced the addition of the "Infanrix Hexa (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022" report to their offering.

Infanrix Hexa [Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), inactivated poliovirus, Hib conjugate vaccine (adsorbed)] is GSK's hexavalent combination vaccine that offers protection against infections caused by diphtheria, tetanus, pertussis, three subtypes of poliovirus, Hib, and all nown subtypes of HBV. Infanrix Hexa contains the antigenic components used in GSK's Pediarix [diphtheria toxoid, tetanus toxoid, inactivated pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin, and inactivated poliovirus subtypes Mahoney, MEF (News - Alert)-1, and Saukett, and yeast-derived HBsAg] and Hiberix (Hib capsular polysaccharide PRP) vaccines (Hiberix package insert, 2012; Pediarix package insert, 2012).

Scope

• Overview of Hepatitis B disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Infanrix Hexa including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Infanrix Hexa for top six countries from 2012 to 2022.
• Sales information covered for the US, France, Germany, Italy, Spain and Canada.

Key Topics Covered:

1. Tables & Figures
2. Introduction
3. Disease Overview
4. Vaccination Recommendations and Coverage Rates
5. Competitive Assessment
6. Infanrix Hexa
7. Appendix

For more information visit http://www.researchandmarkets.com/research/tb2h6k/infanrix_hexa

[ Back To TMCnet.com's Homepage ]